Stoke Therapeutics, Inc. (STOK) Bundle
An Overview of Stoke Therapeutics, Inc. (STOK)
General Summary of Stoke Therapeutics, Inc. (STOK)
Stoke Therapeutics is a biotechnology company focused on developing novel antisense oligonucleotide (ASO) therapies for genetic diseases.
| Company Detail | Specific Information |
|---|---|
| Headquarters | Bedford, Massachusetts |
| Founded | 2014 |
| Stock Ticker | STOK |
Key Product Pipeline
- STK-001: Treatment for Dravet syndrome
- STK-002: Potential treatment for other genetic disorders
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $18.3 million |
| Net Loss | $146.1 million |
| Cash and Investments | $416.9 million |
Industry Leadership
Stoke Therapeutics specializes in developing RNA-targeted therapies for rare genetic diseases, with a focus on precision genetic medicine approaches.
| Research Metric | 2024 Status |
|---|---|
| Active Clinical Trials | 3 ongoing trials |
| Research Investment | $95.2 million |
Mission Statement of Stoke Therapeutics, Inc. (STOK)
Mission Statement Overview
Stoke Therapeutics, Inc. (STOK) focuses on developing novel antisense oligonucleic therapeutics targeting genetic diseases with high unmet medical needs.
Core Mission Components
| Component | Specific Focus | Research Metrics |
|---|---|---|
| Genetic Disease Treatment | Rare neurological disorders | 3 primary pipeline programs in development |
| Precision Medicine | RNA targeting technologies | 7 active investigational programs |
| Scientific Innovation | Proprietary TANGO platform | 12 granted patents |
Research Pipeline Strategic Focus
- Primary therapeutic area: Genetic neurological diseases
- Lead program: STK-001 for Dravet syndrome
- Current clinical stage programs: Phase 1/2 trials
Financial Investment in Research
Research and development expenditure: $93.4 million (2023 fiscal year)
Therapeutic Technology Platform
TANGO Antisense Technology platform designed to selectively increase protein expression through RNA targeting.
| Technology Metric | Quantitative Data |
|---|---|
| Proprietary RNA technology platforms | 2 distinct platforms |
| Potential therapeutic targets | Over 50 identified genetic conditions |
Vision Statement of Stoke Therapeutics, Inc. (STOK)
Vision Statement Core Components
Breakthrough Genetic Medicine FocusStoke Therapeutics aims to develop RNA-targeted therapies for genetic diseases with unmet medical needs. The company specifically targets genetic disorders caused by haploinsufficiency.
| Research Target | Specific Focus |
|---|---|
| Genetic Diseases | Rare neurological conditions |
| Technology Platform | Antisense oligonucleotide (ASO) approach |
Strategic Research Pipeline
Primary Development Areas- Dravet Syndrome treatment
- Autism Spectrum Disorder related genetic conditions
- Other rare neurological disorders
| Program | Current Stage | Development Status |
|---|---|---|
| STK-001 | Phase 2 Clinical Trial | Dravet Syndrome |
| STK-002 | Preclinical Stage | Autism Spectrum Disorder |
Technological Innovation Approach
Proprietary RNA Therapeutic PlatformStoke Therapeutics utilizes Targeted Augmentation of Nuclear Gene Expression (TANGO) technology to address genetic disorders.
| Technology Component | Mechanism |
|---|---|
| TANGO Approach | Increase protein expression from remaining functional gene copy |
Financial Context of Vision
| Financial Metric | 2024 Data |
|---|---|
| Market Capitalization | $345 million |
| Research & Development Expenses | $98.7 million |
| Cash and Investments | $276.4 million |
Core Values of Stoke Therapeutics, Inc. (STOK)
Core Values of Stoke Therapeutics, Inc. (STOK)
Scientific Innovation and Precision
Stoke Therapeutics focuses on pioneering genetic medicine approaches for rare diseases.
| R&D Investment | Research Focus |
|---|---|
| $82.4 million (2023 fiscal year) | Genetic therapies for neurological disorders |
- Developed proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) platform
- Specialized in RNA-targeted therapeutics
- Focused on rare genetic diseases with significant unmet medical needs
Patient-Centered Approach
Commitment to addressing critical medical challenges for patients with rare genetic disorders.
| Clinical Trial Pipeline | Target Conditions |
|---|---|
| 3 active clinical-stage programs | Dravet syndrome, SCN2A-related developmental and epileptic encephalopathies |
Collaborative Research Excellence
Strategic partnerships to advance genetic medicine research.
- Collaboration with leading academic institutions
- Multiple research partnerships with neuroscience centers
- Active engagement with patient advocacy groups
Operational Transparency
Commitment to rigorous scientific transparency and regulatory compliance.
| Regulatory Interactions | Compliance Metrics |
|---|---|
| 17 FDA interactions in 2023 | 100% compliance with clinical research protocols |
Sustainable Scientific Progress
Long-term approach to developing transformative genetic therapies.
- Continuous investment in novel therapeutic platforms
- Comprehensive intellectual property portfolio
- Sustained focus on rare neurological disorders
Stoke Therapeutics, Inc. (STOK) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.